By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Catalyst Pharmaceutical Partners, Inc. 

355 Alhambra Circle, Suite 1500

Coral Gables  Florida  33134  U.S.A.
Phone: 305-529-2522 Fax: 305-529-0933


SEARCH JOBS


Industry
Pharmaceutical






Company News
Catalyst Pharmaceutical Partners, Inc. (CPRX) Appoints David J. Caponera As Vice President Patient Advocacy And Reimbursement 10/28/2014 7:13:30 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present Firdapse Phase 3 Trial Results At The 61st Annual Meeting Of The American Association Of Neuromuscular And Electrodiagnostic Medicine 10/27/2014 7:33:40 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present Top-Line Safety And Efficacy Results From Phase 3 Firdapse Trial At 139th Annual Meeting Of The American Neurological Association 10/8/2014 7:19:36 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Will Hire 25 Staffers After Successful Drug Trial 10/7/2014 6:26:26 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 9/29/2014 1:12:57 PM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Appoints David D. Muth As Executive Vice President, Corporate Development 9/4/2014 8:51:00 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) To Present At Rodman & Renshaw's 16th Annual Global Investment Conference 9/3/2014 7:48:41 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Initiates Phase 1(B) Safety And Tolerance Study For CPP-115 9/2/2014 9:18:50 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Second Quarter 2014 Financial Results 8/14/2014 7:37:38 AM
Catalyst Pharmaceutical Partners, Inc. (CPRX) Provides Updates On Progress Of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 8/11/2014 7:37:15 AM
12345678910...
//-->